Skip to main content
Top
Published in: BMC Infectious Diseases 1/2023

Open Access 01-12-2023 | Epstein-Barr Virus | Research article

Mendelian randomisation identifies priority groups for prophylactic EBV vaccination

Authors: Marisa D. Muckian, James F. Wilson, Graham S. Taylor, Helen R. Stagg, Nicola Pirastu

Published in: BMC Infectious Diseases | Issue 1/2023

Login to get access

Abstract

Background

Epstein Barr virus (EBV) infects ~ 95% of the population worldwide and is known to cause adverse health outcomes such as Hodgkin’s, non-Hodgkin’s lymphomas, and multiple sclerosis. There is substantial interest and investment in developing infection-preventing vaccines for EBV. To effectively deploy such vaccines, it is vital that we understand the risk factors for infection. Why particular individuals do not become infected is currently unknown. The current literature, describes complex, often conflicting webs of intersecting factors—sociodemographic, clinical, genetic, environmental-, rendering causality difficult to decipher. We aimed to use Mendelian randomization (MR) to overcome the issues posed by confounding and reverse causality to determine the causal risk factors for the acquisition of EBV.

Methods

We mapped the complex evidence from the literature prior to this study factors associated with EBV serostatus (as a proxy for infection) into a causal diagram to determine putative risk factors for our study. Using data from the UK Biobank of 8422 individuals genomically deemed to be of white British ancestry between the ages of 40 and 69 at recruitment between the years 2006 and 2010, we performed a genome wide association study (GWAS) of EBV serostatus, followed by a Two Sample MR to determine which putative risk factors were causal.

Results

Our GWAS identified two novel loci associated with EBV serostatus. In MR analyses, we confirmed shorter time in education, an increase in number of sexual partners, and a lower age of smoking commencement, to be causal risk factors for EBV serostatus.

Conclusions

Given the current interest and likelihood of a future EBV vaccine, these factors can inform vaccine development and deployment strategies by completing the puzzle of causality. Knowing these risk factors allows identification of those most likely to acquire EBV, giving insight into what age to vaccinate and who to prioritise when a vaccine is introduced.
Appendix
Available only for authorised users
Literature
2.
go back to reference Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler J. 2020;26:1816–21.CrossRef Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler J. 2020;26:1816–21.CrossRef
3.
go back to reference Sokal EM, Hoppenbrouwers K, Vandermeulen C, et al. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein–Barr virus vaccine in healthy young adults. J Infect Dis. 2007;196:1749–53.CrossRef Sokal EM, Hoppenbrouwers K, Vandermeulen C, et al. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein–Barr virus vaccine in healthy young adults. J Infect Dis. 2007;196:1749–53.CrossRef
4.
go back to reference Kanekiyo M, Bu W, Joyce MG, et al. Rational design of an Epstein–Barr virus vaccine targeting the receptor-binding site. Cell. 2015;162:1090–100.CrossRef Kanekiyo M, Bu W, Joyce MG, et al. Rational design of an Epstein–Barr virus vaccine targeting the receptor-binding site. Cell. 2015;162:1090–100.CrossRef
7.
go back to reference Durovic B, Gasser O, Gubser P, et al. Epstein–Barr virus negativity among individuals older than 60 years is associated with HLA-C and HLA-Bw4 variants and tonsillectomy. J Virol. 2013;87:6526–9.CrossRef Durovic B, Gasser O, Gubser P, et al. Epstein–Barr virus negativity among individuals older than 60 years is associated with HLA-C and HLA-Bw4 variants and tonsillectomy. J Virol. 2013;87:6526–9.CrossRef
8.
go back to reference Friborg JT, Jarrett RF, Koch A, et al. Mannose-binding lectin genotypes and susceptibility to Epstein–Barr virus infection in infancy. Clin Vaccine Immunol. 2010;17:1484–7.CrossRef Friborg JT, Jarrett RF, Koch A, et al. Mannose-binding lectin genotypes and susceptibility to Epstein–Barr virus infection in infancy. Clin Vaccine Immunol. 2010;17:1484–7.CrossRef
11.
go back to reference Hammer C, Begemann M, McLaren PJ, et al. Amino acid variation in HLA class II proteins is a major determinant of humoral response to common viruses. Am J Hum Genet. 2015;97:738–43.CrossRef Hammer C, Begemann M, McLaren PJ, et al. Amino acid variation in HLA class II proteins is a major determinant of humoral response to common viruses. Am J Hum Genet. 2015;97:738–43.CrossRef
12.
go back to reference Scepanovic P, Alanio C, Hammer C, et al. Human genetic variants and age are the strongest predictors of humoral immune responses to common pathogens and vaccines. Genome Med. 2018;10:59.CrossRef Scepanovic P, Alanio C, Hammer C, et al. Human genetic variants and age are the strongest predictors of humoral immune responses to common pathogens and vaccines. Genome Med. 2018;10:59.CrossRef
13.
go back to reference Butler-Laporte G, Kreuzer D, Nakanishi T, Harroud A, Forgetta V, Richards JB. Genetic determinants of antibody-mediated immune responses to infectious diseases agents: a genome-wide and HLA association study. Open Forum Infect Dis. 2020;7: ofaa450.CrossRef Butler-Laporte G, Kreuzer D, Nakanishi T, Harroud A, Forgetta V, Richards JB. Genetic determinants of antibody-mediated immune responses to infectious diseases agents: a genome-wide and HLA association study. Open Forum Infect Dis. 2020;7: ofaa450.CrossRef
14.
go back to reference Sallah N, Miley W, Labo N, et al. Distinct genetic architectures and environmental factors associate with host response to the γ 2-herpesvirus infections. Nat Commun. 2020;11:3849.CrossRef Sallah N, Miley W, Labo N, et al. Distinct genetic architectures and environmental factors associate with host response to the γ 2-herpesvirus infections. Nat Commun. 2020;11:3849.CrossRef
15.
go back to reference Davies NM, Holmes MV, Smith GD. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018;362: k601.CrossRef Davies NM, Holmes MV, Smith GD. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018;362: k601.CrossRef
16.
go back to reference Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562:203–10.CrossRef Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562:203–10.CrossRef
18.
go back to reference Brenner N, Mentzer AJ, Butt J, et al. Validation of multiplex serology detecting human herpesviruses 1–5. PLoS ONE. 2018;13: e0209379.CrossRef Brenner N, Mentzer AJ, Butt J, et al. Validation of multiplex serology detecting human herpesviruses 1–5. PLoS ONE. 2018;13: e0209379.CrossRef
21.
go back to reference Jiang L, Zheng Z, Qi T, et al. A resource-efficient tool for mixed model association analysis of large-scale data. Nat Genet. 2019;51:1749–55.CrossRef Jiang L, Zheng Z, Qi T, et al. A resource-efficient tool for mixed model association analysis of large-scale data. Nat Genet. 2019;51:1749–55.CrossRef
22.
go back to reference Haller T, Kals M, Esko T, Mägi R, Fischer K. RegScan: a GWAS tool for quick estimation of allele effects on continuous traits and their combinations. Brief Bioinform. 2015;16:39–44.CrossRef Haller T, Kals M, Esko T, Mägi R, Fischer K. RegScan: a GWAS tool for quick estimation of allele effects on continuous traits and their combinations. Brief Bioinform. 2015;16:39–44.CrossRef
23.
go back to reference Yavorska OO, Burgess S. MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data. Int J Epidemiol. 2017;46:1734–9.CrossRef Yavorska OO, Burgess S. MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data. Int J Epidemiol. 2017;46:1734–9.CrossRef
24.
go back to reference Ramasubramanyan S, Osborn K, Al-Mohammad R, et al. Epstein–Barr virus transcription factor Zta acts through distal regulatory elements to directly control cellular gene expression. Nucleic Acids Res. 2015;43:3563–77.CrossRef Ramasubramanyan S, Osborn K, Al-Mohammad R, et al. Epstein–Barr virus transcription factor Zta acts through distal regulatory elements to directly control cellular gene expression. Nucleic Acids Res. 2015;43:3563–77.CrossRef
26.
go back to reference Crawford DH, Swerdlow AJ, Higgins C, et al. Sexual history and Epstein–Barr virus infection. J Infect Dis. 2002;186:731–6.CrossRef Crawford DH, Swerdlow AJ, Higgins C, et al. Sexual history and Epstein–Barr virus infection. J Infect Dis. 2002;186:731–6.CrossRef
27.
go back to reference Levine H, Balicer RD, Rozhavski V, et al. Seroepidemiology of Epstein−Barr virus and cytomegalovirus among Israeli male young adults. Ann Epidemiol. 2012;22:783–8.CrossRef Levine H, Balicer RD, Rozhavski V, et al. Seroepidemiology of Epstein−Barr virus and cytomegalovirus among Israeli male young adults. Ann Epidemiol. 2012;22:783–8.CrossRef
28.
go back to reference Xu F-H, Xiong D, Xu Y-F, et al. An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and Epstein–Barr virus activation. J Natl Cancer Inst. 2012;104:1396–410.CrossRef Xu F-H, Xiong D, Xu Y-F, et al. An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and Epstein–Barr virus activation. J Natl Cancer Inst. 2012;104:1396–410.CrossRef
29.
go back to reference Goldacre MJ, Wotton CJ, Yeates DGR. Associations between infectious mononucleosis and cancer: record-linkage studies. Epidemiol Infect. 2009;137:672–80.CrossRef Goldacre MJ, Wotton CJ, Yeates DGR. Associations between infectious mononucleosis and cancer: record-linkage studies. Epidemiol Infect. 2009;137:672–80.CrossRef
30.
go back to reference Hiscock R, Bauld L, Amos A, Platt S. Smoking and socioeconomic status in England: the rise of the never smoker and the disadvantaged smoker. J Public Health. 2012;34:390–6.CrossRef Hiscock R, Bauld L, Amos A, Platt S. Smoking and socioeconomic status in England: the rise of the never smoker and the disadvantaged smoker. J Public Health. 2012;34:390–6.CrossRef
31.
go back to reference Romero-Masters JC, Huebner SM, Ohashi M, et al. B cells infected with Type 2 Epstein–Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection. PLoS Pathog. 2020;16: e1008365.CrossRef Romero-Masters JC, Huebner SM, Ohashi M, et al. B cells infected with Type 2 Epstein–Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection. PLoS Pathog. 2020;16: e1008365.CrossRef
32.
go back to reference Shi T, Balsells E, Wastnedge E, et al. Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: systematic review and meta-analysis. J Glob Health. 2015;5: 020416.CrossRef Shi T, Balsells E, Wastnedge E, et al. Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: systematic review and meta-analysis. J Glob Health. 2015;5: 020416.CrossRef
Metadata
Title
Mendelian randomisation identifies priority groups for prophylactic EBV vaccination
Authors
Marisa D. Muckian
James F. Wilson
Graham S. Taylor
Helen R. Stagg
Nicola Pirastu
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2023
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-023-08031-3

Other articles of this Issue 1/2023

BMC Infectious Diseases 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine